Newsletter | July 30, 2024

07.30.24 -- Maximize The Potential Of Your mRNA-Based Therapeutics

Advancing A LNP Formulation To Clinical And Commercial Manufacturing

Selecting lipids with the appropriate quality impacts both the final lipid nanoparticle (LNP) drug product and the LNP process. Review critical quality considerations for lipids as well as the process requirements necessary for successful commercial-scale manufacturing.

 

Key Benefits Of PCR-Based mRNA Manufacturing For Clinical Development

To unlock the potential of your mRNA therapies and accelerate your mRNA development and manufacturing program, discover the benefits of a novel PCR-based mRNA drug substance manufacturing process. With this innovative and flexible process, mRNA can be provided at all scales and qualities for all stages of a mRNA program life cycle.

 

VIDEO FEATURE

Bringing Your mRNA-Based Drug From Pre-Clinical To Commercial

Watch to explore how you can speed up your mRNA-based drug projects, reduce risks, and shorten time to market with comprehensive and seamless processes from pre-clinical development to commercialization.

• Request Information

 

 

MRNA & LNP CTDMO SERVICES

 

When it comes to developing and bringing mRNA-based therapeutics to market, you need robust, integrated, and consistent processes at every stage from pre-clinical to commercialization. You can rely on a CDMO partner with a 20+ years combined track record in mRNA, Lipids, and LNP manufacturing to provide tailored services supporting you in accelerating your projects, managing risks, and expediting time to market. Learn more.